Phosphate binder use by dialysis patients is associated with a decreased risk of death, researchers reported.
Jorge B. Cannata-Andía, MD, of the Universidad de Oviedo, Spain, and colleagues examined the association between phosphate binder use and survival in 6,797 dialysis patients in the COSMOS study, an observational, prospective three-year follow-up study conducted at 227 dialysis centers in 20 European countries.
In multivariate analysis, patients prescribed phosphate binders had a 29% and 22% lower all-cause and cardiovascular mortality risk, respectively, compared with subjects not prescribed the agents, the researchers reported online ahead of print in Kidney International. This survival benefit remained statistically significant after propensity-score-matching analysis.
Each 10% increment in the case-mix-adjusted facility prescription of phosphate binders was associated with an 8% decreased in the relative risk of death. All single and combined therapies with phosphate binders except aluminum salts demonstrated a survival benefit.